GB2524553C - Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia - Google Patents

Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia

Info

Publication number
GB2524553C
GB2524553C GB1405477.9A GB201405477A GB2524553C GB 2524553 C GB2524553 C GB 2524553C GB 201405477 A GB201405477 A GB 201405477A GB 2524553 C GB2524553 C GB 2524553C
Authority
GB
United Kingdom
Prior art keywords
gdf
growth
monoclonal antibodies
treating cancer
differentiation factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1405477.9A
Other versions
GB2524553B (en
GB201405477D0 (en
GB2524553A (en
Inventor
Wischhusen Jörg
junker Markus
Schafer Tina
Pühringer Dirk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Priority to GB1405477.9A priority Critical patent/GB2524553C/en
Publication of GB201405477D0 publication Critical patent/GB201405477D0/en
Priority to PL15712629T priority patent/PL3122775T3/en
Priority to PT192053213T priority patent/PT3653644T/en
Priority to LTEP19205321.3T priority patent/LT3653644T/en
Priority to ES15712629T priority patent/ES2763859T3/en
Priority to BR112016022013-7A priority patent/BR112016022013B1/en
Priority to DK15712629.3T priority patent/DK3122775T3/en
Priority to ES19205321T priority patent/ES2965626T3/en
Priority to PT157126293T priority patent/PT3122775T/en
Priority to US15/128,604 priority patent/US20170204174A1/en
Priority to HUE19205321A priority patent/HUE064573T2/en
Priority to LTEP15712629.3T priority patent/LT3122775T/en
Priority to JP2016559286A priority patent/JP6865585B2/en
Priority to EP19205321.3A priority patent/EP3653644B1/en
Priority to PL19205321.3T priority patent/PL3653644T3/en
Priority to EP23203704.4A priority patent/EP4316596A3/en
Priority to BR122023027559-4A priority patent/BR122023027559A2/en
Priority to CA2943694A priority patent/CA2943694A1/en
Priority to EP15712629.3A priority patent/EP3122775B1/en
Priority to AU2015238264A priority patent/AU2015238264B2/en
Priority to HUE15712629A priority patent/HUE047398T2/en
Priority to NZ724649A priority patent/NZ724649A/en
Priority to RS20191652A priority patent/RS59700B1/en
Priority to HRP20231514TT priority patent/HRP20231514T1/en
Priority to KR1020167029710A priority patent/KR102520978B1/en
Priority to PCT/EP2015/056654 priority patent/WO2015144855A1/en
Priority to SI201531059T priority patent/SI3122775T1/en
Priority to DK19205321.3T priority patent/DK3653644T3/en
Priority to FIEP19205321.3T priority patent/FI3653644T3/en
Priority to CN201580027932.8A priority patent/CN106536553B/en
Publication of GB2524553A publication Critical patent/GB2524553A/en
Priority to IL248038A priority patent/IL248038B/en
Publication of GB2524553B publication Critical patent/GB2524553B/en
Publication of GB2524553C publication Critical patent/GB2524553C/en
Application granted granted Critical
Priority to US15/912,358 priority patent/US10604565B2/en
Priority to CY20201100008T priority patent/CY1122456T1/en
Priority to HRP20200034TT priority patent/HRP20200034T1/en
Priority to US16/794,406 priority patent/US11760795B2/en
Priority to US16/794,401 priority patent/US11634482B2/en
Priority to IL276405A priority patent/IL276405B/en
Priority to AU2020260440A priority patent/AU2020260440B2/en
Priority to JP2021064572A priority patent/JP2021119138A/en
Priority to JP2023062338A priority patent/JP2023098966A/en
Priority to US18/364,173 priority patent/US20230382987A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
GB1405477.9A 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia Active GB2524553C (en)

Priority Applications (41)

Application Number Priority Date Filing Date Title
GB1405477.9A GB2524553C (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
RS20191652A RS59700B1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
HUE15712629A HUE047398T2 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
LTEP19205321.3T LT3653644T (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
ES15712629T ES2763859T3 (en) 2014-03-26 2015-03-26 Monoclonal Antibodies to Growth and Differentiation Factor 15 (GDF-15), and Uses thereof to Treat Cancer Cachexia and Cancer
BR112016022013-7A BR112016022013B1 (en) 2014-03-26 2015-03-26 MONOCLONAL ANTIBODIES BINDING TO HUMAN GDF-15 AND KIT COMPRISING THE SAME
DK15712629.3T DK3122775T3 (en) 2014-03-26 2015-03-26 MONOCLONAL ANTIBODIES FOR GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND ITS APPLICATIONS FOR TREATING CANCER KAKEKSI AND CANCER
ES19205321T ES2965626T3 (en) 2014-03-26 2015-03-26 Monoclonal antibodies against growth and differentiation factor 15 (GDF-15), and uses thereof to treat cancer cachexia and cancer
PT157126293T PT3122775T (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
US15/128,604 US20170204174A1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
HUE19205321A HUE064573T2 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
LTEP15712629.3T LT3122775T (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
JP2016559286A JP6865585B2 (en) 2014-03-26 2015-03-26 Monoclonal antibody against growth differentiation factor 15 (GDF-15) and its use for treating cancer cachexia and cancer
EP19205321.3A EP3653644B1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
PL19205321.3T PL3653644T3 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
EP23203704.4A EP4316596A3 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
BR122023027559-4A BR122023027559A2 (en) 2014-03-26 2015-03-26 MONOCLONAL ANTIBODIES TO GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), CASE COMPRISING THEM, EXPRESSION VECTOR THAT CODES THEM AND CELL LINE CAPABLE OF PRODUCING THEM
PCT/EP2015/056654 WO2015144855A1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
EP15712629.3A EP3122775B1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
AU2015238264A AU2015238264B2 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
PT192053213T PT3653644T (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
NZ724649A NZ724649A (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
PL15712629T PL3122775T3 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
CA2943694A CA2943694A1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
KR1020167029710A KR102520978B1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
HRP20231514TT HRP20231514T1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
SI201531059T SI3122775T1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
DK19205321.3T DK3653644T3 (en) 2014-03-26 2015-03-26 MONOCLONAL ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15) AND USES THEREOF FOR TREATMENT OF CANCER-RELATED CACHESIA AND CANCER
FIEP19205321.3T FI3653644T3 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
CN201580027932.8A CN106536553B (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15(GDF-15) and their use for treating cancer cachexia and cancer
IL248038A IL248038B (en) 2014-03-26 2016-09-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
US15/912,358 US10604565B2 (en) 2014-03-26 2018-03-05 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
CY20201100008T CY1122456T1 (en) 2014-03-26 2020-01-08 MONOCLONAL ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR 15 (GDF-15), AND USES THEREOF FOR THE THERAPEUTIC TREATMENT OF CANCER CACHESIS AND CANCER
HRP20200034TT HRP20200034T1 (en) 2014-03-26 2020-01-09 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
US16/794,401 US11634482B2 (en) 2014-03-26 2020-02-19 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
US16/794,406 US11760795B2 (en) 2014-03-26 2020-02-19 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
IL276405A IL276405B (en) 2014-03-26 2020-07-30 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
AU2020260440A AU2020260440B2 (en) 2014-03-26 2020-10-28 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
JP2021064572A JP2021119138A (en) 2014-03-26 2021-04-06 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
JP2023062338A JP2023098966A (en) 2014-03-26 2023-04-06 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
US18/364,173 US20230382987A1 (en) 2014-03-26 2023-08-02 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and usesthereof for treating cancer cachexia and cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1405477.9A GB2524553C (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia

Publications (4)

Publication Number Publication Date
GB201405477D0 GB201405477D0 (en) 2014-05-07
GB2524553A GB2524553A (en) 2015-09-30
GB2524553B GB2524553B (en) 2017-06-28
GB2524553C true GB2524553C (en) 2017-07-19

Family

ID=50686995

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1405477.9A Active GB2524553C (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia

Country Status (1)

Country Link
GB (1) GB2524553C (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2818109T3 (en) * 2014-06-23 2021-04-09 Novartis Ag Site-specific protein modifications
US11312766B2 (en) * 2016-04-27 2022-04-26 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465181B2 (en) * 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
EP2441466B1 (en) * 2004-04-13 2014-07-23 St Vincent's Hospital Sydney Limited MIC-1 inhibiting agent
CN102321173B (en) * 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 Humanized macrophage inhibitory factor 1 monoclonal antibody and application thereof
EP3590537A1 (en) * 2012-09-26 2020-01-08 Julius-Maximilians-Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
AR094271A1 (en) * 2012-12-21 2015-07-22 Aveo Pharmaceuticals Inc ANTI-BODY ANTIBODIES

Also Published As

Publication number Publication date
GB2524553B (en) 2017-06-28
GB201405477D0 (en) 2014-05-07
GB2524553A (en) 2015-09-30

Similar Documents

Publication Publication Date Title
IL276405B (en) Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
IL267803A (en) Methods of treating cancer with anti-tim-3 antibodies
HK1245134A1 (en) Treatment of cancer with anti-lap monoclonal antibodies
IL274519A (en) Cd47 antibodies and uses thereof for treating cancer
IL267804A (en) Methods of treating cancer with anti-pd-1 antibodies
IL264674B1 (en) Anti-siglec-7 antibodies for the treatment of cancer
PT3063173T (en) Specific anti-cd38 antibodies for treating human cancers
SG11201704792UA (en) Anti-csf1r antibodies for treating pvns
IL260474B (en) Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
TWI560201B (en) Bi-specific antibodies for treating cancer
SG11201507354QA (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
IL277861A (en) Axl-specific antibodies for cancer treatment
IL250507A0 (en) Anti-ck8 antibodies for use in the treatment of cancers
SG11201702103XA (en) Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
GB2524553B (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB2524552B (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
ZA201707117B (en) Antibody compositions for tumor treatment